Research programme: spinal stem cell therapeutics - DiscGenics

Drug Profile

Research programme: spinal stem cell therapeutics - DiscGenics

Alternative Names: Discogenic cells; Discospheres™; SDCT

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DiscGenics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Intervertebral disc displacement

Most Recent Events

  • 29 Mar 2018 Preclinical trials in Intervertebral disc displacement in USA (Parenteral), before March 2018 (DiscGenics website, March 2018)
  • 03 Oct 2017 DiscGenics plans a clinical trial for Intervertebral disc degeneration in USA in the fourth quarter of 2017
  • 03 Nov 2016 DiscGenics receives patent allowance for Discogenic Cell technology in USA and European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top